. 2020 Sep 9;15:390. doi: 10.1186/s13018-020-01896-z

Table 2.

Characteristics of 4 included studies in this meta-analysis

Study	Area	Design	Duration	Criteria for osteoporosis	Duration	Group	Intervention	n	Age, years	Women, n (%)	BMI
Ebina et al. [28]	Japan	Non-RCT	NR	JSBMR	12 months	BP + ELD	MIN 50 mg/month, ELD 0.75 μg/day	80	71.8 ± 0.9	74 (92.5%)	21.3 ± 0.6
Ebina et al. [28]	Japan	Non-RCT	NR	JSBMR	12 months	BP	MIN 50 mg/month	63	71.7 ± 1.6	58 (92.1%)	21.5 ± 0.6
Iwamoto and Sato [23]	Japan	RCT	April 2012–July 2012	JDC	6 months	BP + ELD	ALE 35 mg weekly or risedronate 17.5 mg weekly, ELD 0.75 μg/day	50	72.3 ± 8.3	50 (100%)	22.5 ± 3.3
Iwamoto and Sato [23]	Japan	RCT	April 2012–July 2012	JDC	6 months	BP	ALE 35 mg weekly or risedronate 17.5 mg weekly	46	69.1 ± 9.9	46 (100%)	22.7 ± 2.5
Suzuki et al. [29]	Japan	RCT	May 2016–August 2017	JSBMR	18 months	BP + ELD	MIN 50 mg/month, ELD 0.75 μg/day	14	68.7 ± 3.1	14 (100%)	20.4 ± 0.7
Suzuki et al. [29]	Japan	RCT	May 2016–August 2017	JSBMR	18 months	BP	MIN 50 mg/month	14	65.8 ± 4.0	14 (100%)	20.1 ± 0.5
Takeuchi et al. [27]	Japan	Non-RCT	March 2014–January 2017	JDC	12 months	BP + ELD	Ibandronate 1 mg injections, ELD NR	94	NR	NR	NR
Takeuchi et al. [27]	Japan	Non-RCT	March 2014–January 2017	JDC	12 months	BP	Ibandronate 1 mg injections	95	NR	NR	NR

ALE alendronate, MIN minodronate, ELD eldecalcitol, BMI body mass index, BP bisphosphonate, JDC Japanese diagnostic criteria, JSBMR Japanese Society for Bone and Mineral Research, NR not reported, RCT randomized controlled trial